prandd

Cancer: New Inhibitor Effective Where Other Treatments Fail

Investigation of targeted treatment in refractory myeloma patients: scientists from Karl Landsteiner University of Health Sciences part of team behind international study. Krems (Austria), 3. December 2019 – A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical…

Marinomed Biotech AG: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay fever

Phase III study comparing Budesolv with standard treatment: Budesolv acts faster against allergic nasal symptoms and asthma-associated symptoms Budesolv requires 85% less active ingredient for the same effect Data presented for the first time at the annual meeting of the American College of Allergy, Asthma & Immunology, Houston, Texas Vienna (Austria), 26. November 2019. Marinomed…

Unknown virus discovered in human body

An international team based in Austria has unearthed a previously unknown type of virus in samples of human bodily fluids. The researchers were looking for viruses that infect bacteria – known as bacteriophages – with an emphasis on those that attack the Escherichia coli (E. coli) bacterium found in the human gut. The team identified a total of 43 bacteriophages in samples of human bodily fluids, particularly in blood samples. The discovery of such phages in the human body is especially significant because they can pass antibiotic resistance genes on to bacteria.

Baking with Electric Shocks

Scientists Explore the Baking of Gluten Free Bread Using a Revolutionary Baking Technology Scientists Explore the Baking of Gluten Free Bread Using a Revolutionary Baking Technology University of Natural Resources and Life Sciences (BOKU) Vienna optimizes baking by direct application of an electrical current. Innovative technology saves energy and time.  Vienna, 24.10.2019 – Electric shocks…

Phage Lysin Stabilizes Vaginal Microbiome.

PhagoMed Accelerates R&D Program Against Bacterial Vaginosis. Vienna (Austria), 23 October 2019: Vienna-based biotech company PhagoMed Biopharma GmbH has discovered a novel drug candidate for the treatment of Bacterial Vaginosis and the re-stabilization of the vaginal microbiome. A dedicated R&D team has been established to develop this unique therapeutic approach, which is based on a…

High drug costs despite public funding in the millions

Ludwig Boltzmann Institute for Health Technology Assessment identifies public funding for the development of high-priced drugs. New investigational search strategy aims at contributing to greater transparency. Three pilot studies were conducted, more will follow. Vienna, 26 September 2019 – EUR 165 million in public and private R&D grants for the discovery and development of a…

International researchers discuss the microbiological safety of water in Vienna

The world’s largest international water hygiene conference is being held in Vienna September 15 th to 20 th The quality of the water used as drinking water, irrigation, aquaculture, food processing or recreational activities has significant public health implications worldwide. Pollution from fecal pathogens continues to be a major concern for health in the environment,…

Antioxidant Does Not Withstand Oxygen: Storability of Vegetable Carotene Severely Affected by Oxygen in Air

EQ BOKU’s high-tech equipment at the University of Natural Resources and Life Sciences, Vienna enables precise analysis of factors influencing the storability of natural colouring concentrates. Vienna, 31 July 2019 – The shelf life of vegetable carotenoids when stored in powdered form is severely affected by oxygen in the storage environment – an effect that…

EU Healthcare Systems: a Reallocation Of Resources Is Urgently Needed

Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel. Vienna, 11. July 2019 – On behalf of the European Commission, international health experts are now making a series of recommendations…

Investors Support Phage Therapy: Novel Approach to Solve the Antibiotics Crisis Receives Further Millions

Vienna (Austria), 27 June 2019: Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further EUR 1.5 million in equity investments to support this novel approach to tackle the antibiotics crisis. The…